Last edition
News about "Phase III MAJESTY trial "
Genentech's Gazyva Shows Strong Phase III Results in Primary Membranous Nephropathy
Phase III MAJESTY trial shows Gazyva significantly improves complete remission rates in primary membranous nephropathy, potentially paving the way for the first targeted therapy for the condition.
Phase III MAJESTY Trial | 17/02/2026 | By News Bureau | 113
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members